Dolby Laboratories Stock: A Smart Buy?

BURBANK, CA – SEPTEMBER 09: General views of the Dolby Laboratories offices on September 09, 2020 in … [+]

Despite already rising more than 2x from its low in March 2020, at the current price of $98 per share, we believe Dolby Laboratories stock (NYSE: DLB) has further upside potential. Dolby stock has increased from $47 to $98 off the 2020 bottom, more than the S&P which increased by around 70% from its lows. Further, the stock is up just around 35% from the level it was at before the pandemic. However, we believe that Dolby stock could rise more than 10% to levels above its recent high of $102, driven by expectations of strong demand and strong Q1 2021 results despite the pandemic. Our dashboard What Factors Drove 58% Change In Dolby Laboratories Stock Between 2018 And Now? has the underlying numbers behind our thinking.

The stock price rise since 2018-end came due to a 10% rise in revenue from $1.05 billion in FY 2018 to $1.16 billion in FY 2020 (Dolby’s fiscal year ends in September). Further, a 3% drop in the outstanding share count, led to revenue-per-share rising by 13% to $11.55 in 2020 from $10.20 in 2018.


Dolby’s P/S (price-to-sales) multiple dropped from around 6x in 2018 to 5.6x by 2019 end, but has since jumped to 8.5x, riding the rally in technology stocks. We believe that the company’s P/S ratio has the potential to rise further in the near term on expectations of continuing demand growth and a favorable shareholder return policy, thus driving the stock price higher.

Where Is The Stock Headed?

The global spread of coronavirus and the resulting lockdowns have led to a drop in demand for medium to large scale sound systems, as theaters have remained closed and large-scale events are not as frequent, due to the pandemic. This has led to a drop in demand for Dolby’s products, which is evident from their Q1 2021 results, where product and services revenue came in at $17 million, half of that in Q1 2020. However, with gaming console and home entertainment system sales rising, licensing revenue jumped 1.5x from $257 million to $373 million over this period. This led to total revenue rising from $291 million to $390 million. With licensing making up the bulk of revenue, COGS and operating expenses came in low, leading to operating margins jumping from 16.7% to a strong 42.2%. This helped drive EPS from $0.49 to $1.34 over this period.

We expect licensing revenue to stay strong in the medium term, and with the lockdowns being lifted and theaters re-opening, we believe the company will see a revival in products and services revenue as well. These factors will raise investor expectations further, driving up the company’s P/S multiple. We believe that Dolby Laboratories stock can rise more than 10% from current levels, to new highs over $102.

High Quality Portfolio

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio to beat the market, with over 100% return since 2016, versus 55% for the S&P 500. Comprised of companies with strong revenue growth, healthy profits, lots of cash, and low risk, it has outperformed the broader market year after year, consistently.

See all Trefis Price Estimates and Download Trefis Data here

What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams

Led by MIT engineers and Wall Street analysts, Trefis (through its dashboards platform helps you understand how a company’s products, that you